當(dāng)前位置: 首頁 - 產(chǎn)品目錄 - 小分子抑制劑
MG 132 (MG-132)
貨號 | J6288 | 售價(元) | 3929 |
規(guī)格 | 50mg | CAS號 | 133407-82-6 |
- 產(chǎn)品簡介
- 相關(guān)產(chǎn)品
產(chǎn)品信息
貨號 |
名稱 |
規(guī)格 |
價格/元 |
J6282 |
MG 132 (MG-132) |
5mg |
622 |
J6284 |
MG 132 (MG-132) |
10 mg |
1091 |
J6286 |
MG 132 (MG-132) |
25 mg |
2183 |
J6288 |
MG 132 (MG-132) |
50 mg |
3929 |
產(chǎn)品簡介:
MG-132是一種蛋白酶體抑制劑,IC50為100 nM,也抑制鈣蛋白酶,IC50為1.2 μM。MG132通過誘導(dǎo)細(xì)胞周期停滯以及引發(fā)細(xì)胞凋亡來抑制HeLa細(xì)胞的生長。MG-132 (10 μM) 通過抑制蛋白酶體介導(dǎo)的IκBα降解,有效抑制A549細(xì)胞中TNF-α誘導(dǎo)的NF-κB活化。體內(nèi)研究中,MG-132(ip,0.1 mg/kg/day)通過調(diào)節(jié)ERK1/2和JNK1信號通路,減輕壓力超負(fù)荷引起的心臟肥大。MG-132治療通過下調(diào)肌肉特異性泛素連接酶atrogin-1/MAFbx 和MuRF-1 mRNA,顯著減少小鼠體內(nèi)固定化誘導(dǎo)的骨骼肌萎縮。
本品以凍干粉形式提供,純度≥98%,可溶于DMSO或無水乙醇配制成儲存液,之后用培養(yǎng)基或生理緩沖液稀釋到需要的工作濃度即可。
產(chǎn)品性質(zhì)
英文別名(English Synonym): MG132; MG 132; Z-Leu-Leu-Leu-CHO; Z-Leu-Leu-Leu-al; Z-LLL-CHO;Carbobenzoxy-L-leucyl- L-leucyl-L-leucinal
化學(xué)名(Chemical Name):N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-L-leucinamide
靶點(Target):ChTL(20S Proteasomes)/ 0.22 μM, PGPH(20S Proteasomes)/2.95 μM,TL(20S Proteasomes)/34.4 μM
CAS 號(CAS NO.):133407-82-6
分子式(Molecular Formula):C26H41N3O5
分子量(Molecular Weight):475.6
外觀(Appearance):白色至類白色固體
純度(Purity):>98%
溶解性(Solubility):溶于DMSO(30 mg/ml),無水乙醇(20mg/ml)
運輸與保存方法
冰袋運輸。粉末直接保存于-20 oC,有效期2年。溶于DMSO、乙醇。建議分裝后-20oC避光保存,避免反復(fù)凍存,至少可存放6個月。
相關(guān)產(chǎn)品:
貨號 |
產(chǎn)品名稱 |
規(guī)格 |
價格/元 |
WU017 |
3-Methyladenine (3-MA) 3-甲基腺嘌呤 |
10mg |
238 |
J9883 |
Rapamycin (Sirolimus) 雷帕霉素 |
10mg |
248 |
WU034 |
Wortmannin (25mg/ml in DMSO) 渥曼青霉素 |
1mg |
390 |
WU077 |
Monensin, Sodium Salt 莫能霉素(鈉鹽) |
100mg |
460 |
使用濃度
【具體使用濃度請參考相關(guān)文獻(xiàn),并根據(jù)自身實驗條件(如實驗?zāi)康?,?xì)胞種類,培養(yǎng)特性等)進行摸索和優(yōu)化?!?span>
1) 使用前置于室溫回溫至少20min,并經(jīng)短暫離心使得粉末/固體落在管底后再溶解。
2) 稱取適量粉末溶于無水DMSO配制儲存液(比如20 mg/ml,取500μl DMSO 加入10mg MG-132,渦旋混勻,直至完全溶解)。按照單次用量分裝后-20oC保存,避免反復(fù)凍存,至少1個月穩(wěn)定, 也可置于-80℃延長保存周期。
3) 根據(jù)具體實驗應(yīng)用,選擇合適的溶劑稀釋到所需濃度。體外細(xì)胞實驗,常用的工作濃度是5-50 μM,處理時間1-24h。本品的具體工作濃度和處理時間請參考相關(guān)文獻(xiàn),并根據(jù)自身實驗條件(如實驗?zāi)康模?xì)胞種類,培養(yǎng)特性等)進行摸索和優(yōu)化。
相關(guān)實驗(數(shù)據(jù)來自于公開發(fā)表的文獻(xiàn),僅供參考)
使用方法【源自文獻(xiàn),僅作參考】
文獻(xiàn)1,MacLaren AP et al. p53-dependent apoptosis induced by proteasome inhibition in mammary epithelial cells. Cell Death Differ. 2001 Mar;8(3):210-8. PMID: 11319603
體外研究:
細(xì)胞類型(Cell type):HeLa cells exposed to 10 or 100 J/m2 UV (254 nm) using a UV crosslinker.
藥物配制(Preparation):MG132 dissolved in DMSO and diluted in DMEM.
實驗方法(Assay):HeLa cells were grown to about 60% confluence in DMEM at 37°C in the presence of 5% CO2. MG132 dissolved in DMSO was added (5 μM final concentration). For mock treatment, DMSO alone was added. Cells were incubated for 1 h before UV irradiation. For UV treatment, medium in the Petri dishes was removed, and cells were exposed to 10 or 100 J/m2 UV (254 nm) using a UV crosslinker. Medium containing MG132 or DMSO alone was added back to the respective Petri dishes, and cells were transferred back to the incubator for the time course experiment.
文獻(xiàn)2,Inoue S et al.The effect of proteasome inhibitor MG132 on experimental in?ammatory bowel disease. Clin Exp Immunol. 2009 Apr;156(1):172-82. PMID: 19220323
體內(nèi)研究:
動物模型(Animal Model):Experimental murine colitis models: IL-10-deficient (IL-10?/?) mice and dextran sulphate sodium (DSS)-induced colitis
藥物配制(Preparation):MG132 was dissolved in dimethyl sulphoxide (DMSO) and then diluted in 500 μl sterile phosphate-buffered saline (PBS) for injection.
注射劑量(Dosages):Female IL-10?/? mice at 4 weeks of age were divided into four groups and treated with intraperitoneal injection three times a week as follows: group A, 0·01% DMSO as the control; group B, 0·6 μmol/kg MG132; group C, 3·0 μmol/kg MG132; and group D, 15·0 μmol/kg MG132. All mice were killed after 4 weeks of treatment by cervical dislocation under ether anaesthesia.
Female C57BL/6 mice were given 3% DSS (molecular weight 36–50 kDa) in their drinking water for 5 days, and then switched to regular drinking water. Mice were injected intraperitoneally with 15·0 μmol/kg MG132 (prepared in the same way as for IL-10?/? mice) or 0·01% DMSO as the control three times a week from day 0 to the end of the experiment. On day 10, the mice were killed.
給藥途徑(Administration):Intraperitoneal (i.p.) injection
參考文獻(xiàn)
1. Tsubuki S, et al. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J Biochem. 1996 Mar;119(3):572-6.
2. Braun HA, et al. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J Biol Chem. 2005 Aug 5;280(31):28394-401.
3. Han YH, et al. The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. Oncol Rep. 2009 Jul;22(1):215-21.
4. Chen B, et al. MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Acta Biochim Biophys Sin (Shanghai). 2010 Apr;42(4):253-8.
5. Caron AZ, et al. The proteasome inhibitor MG132 reduces immobilization-induced skeletal muscle atrophy in mice. BMC Musculoskelet Disord. 2011 Aug 15;12:185.